## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.90 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-13.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($988.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company**
- Source: Eli Lilly and Company | 20251201T205230 | Bullish | Relevance: 100%
- Eli Lilly and Company announced a price reduction for Zepbound® (tirzepatide) single-dose vials on its digital healthcare platform, LillyDirect. This move aims to improve access and affordability for people living with obesity in the United States, following a previous price reduction for multi-dose pens. Patients can now access various doses of Zepbound single-dose vials at lower prices through the Zepbound Self Pay Journey Program.

**2. Eli Lilly cuts Zepbound price to widen access for obesity drug**
- Source: Reuters | 20251201T130200 | Bullish | Relevance: 99%
- Eli Lilly has reduced the price of its popular obesity drug Zepbound to improve affordability and access for U.S. patients amidst surging demand for weight-loss therapies. The price cuts affect single-dose vials and follow similar reductions for multi-dose pens, which are awaiting FDA approval. This strategic move aims to address cost and coverage barriers, further solidifying Lilly's position in the rapidly expanding obesity drug market.

**3. Eli Lilly Becomes First Trillion-Dollar Health Company**
- Source: Clinical Pain Advisor | 20251201T153609 | Bullish | Relevance: 99%
- Eli Lilly has become the first healthcare company globally to achieve a $1 trillion market value, driven largely by the success of its diabetes drug Mounjaro and weight-loss drug Zepbound. The company's stock has surged over 36% this year due to rising demand for its treatments, with Mounjaro and Zepbound generating billions in sales. Eli Lilly anticipates continued growth through expanded insurance coverage, new approvals, and the planned release of an oral weight-loss drug.

**4. Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle**
- Source: Fox Business | 20251201T134300 | Somewhat-Bullish | Relevance: 99%
- Eli Lilly has announced new price cuts for its weight loss drug Zepbound through its LillyDirect platform to enhance patient access and compete in the growing weight loss drug market. Single-dose vials will now cost $299 per month for patients with valid prescriptions, with other doses also seeing significant reductions. This strategic move aims to leverage LillyDirect for direct-to-consumer sales, intensifying competition with rivals like Novo Nordisk.

**5. Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers**
- Source: Bloomberg.com | 20251201T130000 | Neutral | Relevance: 98%
- Eli Lilly & Co. has announced a price cut of up to 20% for the introductory doses of its weight-loss drug Zepbound for cash-paying buyers. Starting Monday, the lowest dose will cost $299 a month, a $50 discount, while the next higher dose will be $399, marking a significant reduction to compete with rival Novo Nordisk A/S. The company is also lowering prices for higher doses by approximately $50.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-13.1% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $208M sold (30 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 8 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 32.5x attractive for 36% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (8 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $890.8B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 32.5 |
| Current P/E | 44.2 |
| YoY Growth | 35.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 14.0% to 0.9% (-13.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 (-3.7%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-3.59), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.88% (CS: 69) | Neutral |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | -3.59 | Bearish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.170x | Above |
| vs SMA200 | 1.292x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1046.12
- **Stop Loss:** $988.50 (5.5% risk)
- **Target:** $1161.36 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 17
- **Position Value:** $17,784.04
- **Portfolio %:** 17.78%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*